• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Alpha Cognition Inc.

    10/3/25 4:05:22 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Alpha Cognition Inc.

    (Name of Issuer)


    Common Stock, no par value

    (Title of Class of Securities)


    02074J501

    (CUSIP Number)


    10/01/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    02074J501


    1Names of Reporting Persons

    Opaleye Management Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,875,142.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,875,142.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,875,142.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.97 %
    12Type of Reporting Person (See Instructions)

    IA, CO


    SCHEDULE 13G

    CUSIP No.
    02074J501


    1Names of Reporting Persons

    Opaleye, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,875,142.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,875,142.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,875,142.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.97 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Based on 20,902,104 Common Shares outstanding as reported by Alpha Cognition, Inc. in its Form 424B5 filed with the SEC on October 1, 2025.


    SCHEDULE 13G

    CUSIP No.
    02074J501


    1Names of Reporting Persons

    James Silverman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,875,142.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,875,142.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,875,142.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.97 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Alpha Cognition Inc.
    (b)Address of issuer's principal executive offices:

    1452 Hughes Rd. Ste. 200, Grapevine, TX 76051
    Item 2. 
    (a)Name of person filing:

    Opaleye Management Inc. Opaleye, L.P. James Silverman This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to shares directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the shares reported herein.
    (b)Address or principal business office or, if none, residence:

    One Boston Place, 26th Floor, Boston, MA 02108
    (c)Citizenship:

    Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Massachusetts James Silverman - USA
    (d)Title of class of securities:

    Common Stock, no par value
    (e)CUSIP No.:

    02074J501
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,875,142.00
    (b)Percent of class:

    8.97%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,875,142.00

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,875,142.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Opaleye Management Inc.
     
    Signature:/s/ James Silverman
    Name/Title:President
    Date:10/03/2025
     
    Opaleye, L.P.
     
    Signature:/s/ James Silverman
    Name/Title:General Partner
    Date:10/03/2025
     
    James Silverman
     
    Signature:/s/ James Silverman
    Name/Title:Individually
    Date:10/03/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement by and among the reporting persons

    Get the next $ACOG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Alpha Cognition Inc.

    SCHEDULE 13G - Alpha Cognition Inc. (0001655923) (Subject)

    10/3/25 4:05:22 PM ET
    $ACOG

    Alpha Cognition Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Alpha Cognition Inc. (0001655923) (Filer)

    10/1/25 9:03:19 PM ET
    $ACOG

    SEC Form 424B5 filed by Alpha Cognition Inc.

    424B5 - Alpha Cognition Inc. (0001655923) (Filer)

    10/1/25 5:27:38 PM ET
    $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

    Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders Company's total cash position expected to be approximately $70 million following closing Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. The gross proceeds of the offering are approximately $35.0 million, before deducting underwriting disc

    9/30/25 11:14:00 PM ET
    $ACOG

    Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

    Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an underwritten public offering. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares (and common shares underlying pre-funded warrants) sold in the proposed public offering, on the same terms and conditions. The propos

    9/30/25 4:58:00 PM ET
    $ACOG

    Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

    Alpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025 Date/Time: Friday, September 5, 7:00 a.m. ET H.C. Wainwright & Co. Healthcare Conference 2025 Date/Time: Tuesday, September 9, 2:00 p.m. ET Presentation transcripts will be made available on Alpha Cognition's website following the events and will remain accessible for 30 days. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial st

    8/28/25 1:00:00 PM ET
    $ACOG

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wills Robert James bought $127,328 worth of shares (15,000 units at $8.49) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/21/25 12:36:53 PM ET
    $ACOG

    Director Mertz Phillip Joseph sold $250,002 worth of shares (27,778 units at $9.00), decreasing direct ownership by 55% to 22,462 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/20/25 4:26:14 PM ET
    $ACOG

    Director Mertz Leonard Powell bought $250,002 worth of shares (27,778 units at $9.00) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/20/25 4:06:08 PM ET
    $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

    H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

    3/18/25 7:48:36 AM ET
    $ACOG

    $ACOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wills Robert James bought $127,328 worth of shares (15,000 units at $8.49) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/21/25 12:36:53 PM ET
    $ACOG

    Director Mertz Leonard Powell bought $250,002 worth of shares (27,778 units at $9.00) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/20/25 4:06:08 PM ET
    $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

    1/14/25 8:30:00 AM ET
    $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    View All

    Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.

    8/14/25 8:30:00 AM ET
    $ACOG

    Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

    Conference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6 - Participant

    8/4/25 8:30:00 AM ET
    $ACOG

    Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

    Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is

    5/15/25 8:30:00 AM ET
    $ACOG